NL-OMON36725
Completed
Not Applicable
An Open-Label Two-Way Drug-Drug Interaction Study to Assess the Effect of Tenofovir on the Pharmacokinetics of BMS-790052 and the Effect of BMS-790052 on the Pharmacokinetics of Tenofovir in Healthy Subjects - BMS-790052/tenofovir drug-drug interaction study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatitis C
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 21
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 18\-49 years, inclusive
- •BMI: 18\.0 \- 32\.0 kg/m2, inclusive
- •Women of child bearing potential should use adequate contraception (e.g., double barrier method) until at least 12 weeks after last dose of study medication
Exclusion Criteria
- •\- Any significant acute or chronic medical illness (especially renal disease).
- •\- Current or recent (within 3 months of study drug administration) gastrointestinal disease indicated as clinically relevant by the Medical Investigator.
- •\- Any major surgery within 4 weeks of study drug administration.
- •\- Any gastrointestinal surgery that could impact upon the absorption of study drug.
- •\- Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 90 days of study drug administration.
- •\- Blood transfusion within 90 days of study drug administration.
- •\- Inability to tolerate oral medication.
- •\- Inability to swallow oral medication in the form of tablets or capsules.
- •\- Inability to be venipunctured and/or tolerate venous access.
- •\- Smoking more than 5 cigarettes per day.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An Open-label Drug-Drug Interaction Study to Assess the Effects ofNemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Serve Atopic DermatitisModerate-to-severe atopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2020-000229-24-BGGalderma S.A.25
Unknown
Phase 3
An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult maleHealthy adult maleJPRN-jRCT2080221293SANWA KAGAKU KENKYUSHO CO.,LTD.12
Completed
Not Applicable
A Phase I, open-label, drug-drug interaction study between multiple oral doses of GLPG1972 and a single dose of midazolam in healthy male subjects.NL-OMON44611Galapagos NV18
Active, not recruiting
Phase 1
A study in healthy volunteers to discover how the test medicine interacts with other approved medicines1. Non-alcoholic steatohepatitis (NASH)2. Antipsychotic-induced weight gain (AIWG)Not ApplicableISRCTN10379288Corcept Therapeutics (United States)30
Completed
Not Applicable
An Open-Label Drug-Drug Interaction Study in Healthy Male Subjects to Explore the Effects of Single and Multiple Doses of JNJ-39393406 on the Pharmacokinetics of a Single Oral Dose of Midazolamalzheimerpsychose1005716710039628NL-OMON33240Janssen-Cilag12